Skip to main content

Table 3 Comparisons between both waves regarding the type of neuropathy and outcome

From: Characteristics of COVID and post COVID polyneuropathies in adults and pediatrics: an Egyptian sample

   Neuropathy type P
   AIDP AMSAN Demyelinating with secondary axonal CIDP like  
Wave 1st wave 11 (47.8%) 5 (21.7%) 3 (13.0%) 4 (17.4%) 0.193
2nd wave 14 (73.7%) 3 (15.8%) 2 (10.5%) 0 (0.0%)
   Outcome P
   Full improvement Minimal improvement No improvement and needed second treatment to improve  
Wave 1st wave 14 (60.9%) 3 (13.0%) 6 (26.1%) 0.084
2nd wave 17 (89.5%) 0 (0.0%) 2 (10.5%)
  1. AIDP acute inflammatory demyelinating polyneuropathy, AMSAN acute motor sensory axonal neuropathy, CIDP chronic inflammatory demyelinating polyneuropathy